Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A/T/S vs SEIZALAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
Status epilepticus,Acute repetitive seizures,Seizure clusters
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
70-90% bound to serum albumin.
Approximately 98% bound to albumin.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
1.0–1.5 L/kg; reflects extensive tissue distribution.
Topical: 1–5% (minimal systemic absorption).
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
No specific adjustment required; drug is not renally eliminated.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
None.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A/T/S vs SEIZALAM, answered by our medical review team.
A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A/T/S and SEIZALAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A/T/S and SEIZALAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.